Dupilumab provides significant clinical benefit in a phase 3 trial in adolescents with uncontrolled atopic dermatitis irrespective of prior systemic immunosuppressant use

  1. Deleuran, M.
  2. Marcoux, D.
  3. DE BRUIN-WELLER, M.S.
  4. Irvine, A.D.
  5. Baselga, E.
  6. Ahn, K.
  7. Castro, A.P.
  8. Bansal, A.
  9. Chao, J.
  10. Bégo-Le Bagousse, G.
  11. Rossi, A.B.
Aldizkaria:
Acta Dermato-Venereologica

ISSN: 1651-2057,  0001-5555

Argitalpen urtea: 2021

Alea: 101

Zenbakia: 7

Mota: Artikulua

DOI: 10.2340/00015555-3848 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus